China Resources Sanjiu Medical & Pharma (000999) Earnings Surge: FY Net Income Rises 18% to 3.37B Yuan

China Resources Sanjiu Medical & Pharma on Smartkarma

Analysts on Smartkarma are providing valuable insights on China Resources Sanjiu Medical & Pharma, as seen in the research reports by Xinyao (Criss) Wang. In the report titled “China Healthcare Weekly (Feb.16)- Update on CR Sanjiu’s Acquisition of Tasly, the Impact of US Tariff,” Xinyao highlights that China’s biotech companies may have sold core assets too early, missing out on future benefits. Despite short-term US tariff impacts, the industry is expected to undergo an upgrade. The acquisition of Tasly by CR Sanjiu is progressing well, with approvals received, hinting at a potential completion in Q1 2025.

In another report by Xinyao titled “China Healthcare Weekly (Feb.2)- Update on CR Sanjiu’s Acquisition of Tasly, China Biotech’s Outlook,” the focus is on the need for Chinese biotech firms to develop new blockbuster products for sustained growth. A “supply side reform” is noted to favor first-tier biotechs. The ongoing acquisition of Tasly by China Resources Sanjiu Medical & Pharma is highlighted, with a caution that the deal might extend to the first half of 2025 if approval processes delay. These analyses provide essential guidance for investors interested in the evolving landscape of China’s healthcare industry.

A look at China Resources Sanjiu Medical & Pharma Smart Scores

Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma

China Resources Sanjiu Medical & Pharmaceutical Co., Ltd., a company engaged in manufacturing and marketing medicines, healthcare products, and medical instruments, has been assessed using the Smartkarma Smart Scores. The company has received a high score in Dividend, Growth, Resilience, and Momentum, indicating a positive outlook in these areas. With a strong emphasis on dividends and growth potential, coupled with solid resilience and momentum, China Resources Sanjiu Medical & Pharma seems well-positioned for long-term success.

Having achieved favorable scores across various key factors, China Resources Sanjiu Medical & Pharma appears to be a promising investment opportunity. The company’s operations span across pharmaceutical trading, printing, food manufacturing, real estate development, and provision of medical services, diversifying its revenue streams and enhancing its growth prospects. Investors may find the company attractive based on its solid performance in the assessed categories, setting a positive tone for its future performance in the medical and pharmaceutical industry.

Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.

💡 Before it’s here, it’s on Smartkarma